Tacrolimus-loaded PLGA implants: in vivo release and ocular toxicity

Curr Eye Res. 2014 Jan;39(1):99-102. doi: 10.3109/02713683.2013.819927.

Abstract

Purpose: To evaluate the in vivo release and ocular toxicity of a tacrolimus-loaded PLGA intravitreal implant.

Methods: Tacrolimus-loaded PLGA implants were inserted into the vitreous cavity of rabbits' eye. At different time points, the vitreous was retrieved and the concentration of tacrolimus released from the implants was determined. Clinical examination was performed to evaluate the implant tolerance.

Results: PLGA implants provided controlled and prolonged release of tacrolimus. Approximately 99.97% of the drug was released from the devices at 6 weeks. Ophthalmic examination revealed no evidence of toxic effects of implants.

Conclusions: Tolerance and feasibility of the tacrolimus-loaded PLGA implants, as sustained intraocular drug delivery systems, were demonstrated.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Biocompatible Materials / pharmacology
  • Biocompatible Materials / toxicity
  • Choroid / drug effects
  • Drug Delivery Systems / adverse effects
  • Feasibility Studies
  • Female
  • Immunosuppressive Agents / pharmacology
  • Immunosuppressive Agents / toxicity
  • Intravitreal Injections
  • Lactic Acid / toxicity*
  • Polyglycolic Acid / toxicity*
  • Polylactic Acid-Polyglycolic Acid Copolymer
  • Prostheses and Implants / adverse effects*
  • Rabbits
  • Retina / drug effects
  • Sclera / drug effects
  • Tacrolimus / pharmacology
  • Tacrolimus / toxicity*
  • Uveitis / drug therapy*
  • Vitreous Body / drug effects

Substances

  • Biocompatible Materials
  • Immunosuppressive Agents
  • Polylactic Acid-Polyglycolic Acid Copolymer
  • Polyglycolic Acid
  • Lactic Acid
  • Tacrolimus